Identifai Genetics (ASX: ID1) - An IPO Built on Non-Invasive Prenatal Testing
The Identifai Genetics IPO seeks A$10 million at 20 cents for Windrose, a non-invasive prenatal test designed to screen a baby's genes from the mother's blood. The company says an interim analysis of 50 high-risk pregnancies detected every condition confirmed by invasive testing. The larger US study has not started, and there is no material revenue. The offer closes 29 September 2026.
The Identifai Genetics IPO brings an Israeli prenatal genetics company to the ASX. Non-invasive prenatal testing, or NIPT, reads DNA fragments in a pregnant woman's blood. Most are her own. A small share comes from the placenta and usually matches the baby's. Identifai wants that blood draw to screen for many more single-gene conditions. Trading is expected to start on 16 October 2026 [R2].
THE SOURCE DOCUMENT Identifai Genetics Limited, Prospectus, 2 September 2026, lodged with ASIC. Available from the company at identifai-genetics.com/prospectus [R1]. Recent Samso ASX IPO reviews include the Ceretas IPO and the Overwatch Technologies IPO. |
The Identifai Genetics IPO Offer
The offer is 50,000,000 shares at A$0.20, raising A$10,000,000 before costs (TABLE 01). The full amount is also the minimum. The offer is not underwritten, which means no broker has agreed to take up shares the public does not [R1].
Lead manager Aesir Corporate, the broker running the offer, receives a 6 per cent cash fee, A$600,000, plus 10,154,970 options at 25 cents that the company values at A$899,000. The prospectus puts the total at A$1,499,000, or 14.99 per cent of the IPO funds.
![TABLE 01. Identifai Genetics IPO, key terms at full subscription. Columns: Item, As published. Item Offer price, As published A$0.20 per share. Item Shares offered, As published 50,000,000. Item Gross proceeds, also the minimum, As published A$10,000,000. Item Underwritten, As published No. Item Shares on issue after the offer, As published 191,979,023. Item Fully diluted share capital, As published 238,857,169. Item Market capitalisation, undiluted, As published A$38,395,805. Item Market capitalisation, fully diluted, As published A$47,771,433. Item Offer closes, As published 5pm WST, 29 September 2026. Item Expected first trading, As published 16 October 2026. Source: Identifai Genetics Limited, Prospectus, 2 September 2026, Key Offer Information and Section 4.17 [R1].](https://static.wixstatic.com/media/8d6c37_9a6889e63632433694e542a0fafdfb65~mv2.png/v1/fill/w_980,h_715,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/8d6c37_9a6889e63632433694e542a0fafdfb65~mv2.png)
What Windrose Does, and the Gap It Targets
Standard NIPT screens for extra or missing chromosomes, such as Down syndrome. It does not look for most single-gene conditions, disorders caused by one faulty gene, such as cystic fibrosis. The prospectus notes that American College of Obstetricians and Gynecologists guidance does not support routine screening for them using cfDNA, the cell-free DNA in the mother's blood [R1].
The usual route is carrier screening of both parents, then possibly amniocentesis, where a needle takes fluid from the womb. Windrose is designed to test the mother. If she carries a faulty gene, the same sample is used to check whether the baby inherited her copy. No sample from the father is needed. It is a screen, so a high-risk result leads to counselling and possibly invasive testing. The company says the father is unavailable for testing in more than 50 per cent of carrier-positive cases.
Most of the prospectus describes a panel of "more than 280" genes. Section 4.3(b) also refers to "the full list of 319 genes" (TABLE 02).
The Evidence So Far
The prospectus says an Israeli study of 18 families was published in Prenatal Diagnosis. An interim analysis of 50 high-risk cases in a US and Israeli study reported that Windrose detected every condition confirmed by invasive testing. The number of such cases is not given. Across all genes it scored 0.94 on AUC, or area under the curve, where 0.5 is a coin toss and 1.0 is perfect.
For 13 samples run through Inocras, the US laboratory partner, the prospectus reports 92 per cent sensitivity, real cases caught, and 94 per cent specificity, healthy cases cleared. It does not give the counts behind them. It also reports a top-rated abstract award at ACMG 2026, a US genetics meeting [R1].
Chair Yoseph Bornstein calls the 50-pregnancy results "extremely encouraging" in his letter. The next step is a clinical validation study of about 600 patients across six to eight US sites, planned to start in 2026 [R1].
How the Business Is Put Together
A new Australian parent, incorporated in February 2026, owns Identifai Israel, the operating business. It also owns a Delaware subsidiary setting up the US laboratory in San Diego (FIG. 01).
Three parties have claims on future sales. Ramot, Tel Aviv University's technology company, takes 4 per cent where a patent covers the product and 3 per cent where one does not. The Israel Innovation Authority granted about US$2.1 million. It is repaid from royalties of about 3 to 5 per cent in Sections 4.15 and 6, and 3 per cent in Note 5 to the accounts. Moving the technology out of Israel needs the Authority's approval and can cost up to six times the grants. The Binational Industrial Research and Development (BIRD) Foundation grant of up to US$1 million is not yet under a signed agreement. It is repaid jointly with Inocras from 5 per cent of sales. Both grant royalties are capped and stop once repaid [R1].
Where the A$10 Million Goes
Funds available are A$11,386,000, made up of the raise plus A$1,386,000 of cash held at 31 August 2026. Research and development takes the largest share (FIG. 02). The directors say the funds cover two years [R1].
Identifai Israel used US$2.2 million in operating cash in 2025 and lost US$1.7 million. Its auditor, Deloitte Israel, flagged a material uncertainty about whether Identifai Israel can keep operating as a going concern. On Samso's arithmetic, cash after offer costs is about A$10 million. Set against the A$38.4 million value at the offer price, that leaves about A$28 million for the business.
The Register, the Performance Rights and the Escrow
Four holders will own about 43 per cent of the shares after the offer, by Samso's count, including Shizim VS, which is linked to two directors. The chief financial officer, Rotem Caspi, is the daughter of director Kobi Caspi. The May 2026 raisings were priced at about 10 cents a share on Samso's arithmetic, and the August pre-IPO round at 16 cents. The 9,436,035 swap options, which replaced Identifai Israel options held by staff and service providers, convert at US$0.06, about A$0.08 at the expert's rate [R1].
There are 25,768,560 performance rights, which turn into shares only if targets are met. Half need CLIA certification, the US federal certificate for the laboratory, announced by 31 December 2026. The other half need US$3.0 million of audited annual recurring revenue by 31 December 2028. Both also need a volume-weighted average share price of at least 25 cents over 20 consecutive trading days. Related parties receive 13,480,090 of the rights (FIG. 03).
The independent expert, Pendragon Capital, found the performance rights fair and reasonable. It found the swap options "not fair but reasonable". On the expert's figures, full exercise at US$0.06 lowers the implied value of a share to about A$0.1946. Pendragon's reasons include that they are existing entitlements. Escrow, the ASX rule that stops some holders selling for a period after listing, will apply for up to 24 months. Escrowed amounts are announced before trading. The company expects a free float, the shares free to trade, of about 26 per cent [R1].
What the Next Stage Will Show
The results so far come from small groups. Fifty cases were analysed out of more than 200 recruited. The planned 600-patient study will test a larger group. How insurers will pay is still to be worked out. The company may start with self-paying patients, including in vitro fertilisation (IVF) patients. The prospectus notes that a US billing code does not guarantee an insurer will pay.
On patents, the Chair's letter says they are granted in the US, China and Israel. Section 4.14 says the US, China and Hong Kong. The independent IP report says China, Hong Kong and Israel, with the US patent approved and its issue fee paid. On Inocras, the risk section says losing the agreement may disrupt the business. Section 9.4 says another laboratory could be found without material disruption [R1].
Near-term Milestones to Watch
The company targets CLIA certification in the fourth quarter of 2026. Initial US commercialisation and the study's start are set for 2026, and interim clinical results for the second half of 2027 [R1].
Samso Concluding Comments
Identifai is aiming at a real gap. When a mother is a carrier and the father cannot be tested, most conditions still need an invasive test. Of the rival tests the prospectus names that screen the baby, the largest covers 56 genes (TABLE 02). The science comes from founder Professor Noam Shomron's laboratory at Tel Aviv University, where the core algorithms have been developed since 2016. A CLIA laboratory director and a sequencing partner are in place [R1].
At about A$28 million for the business, investors pay for a test with interim results in a small group of high-risk pregnancies. The study that decides whether doctors and payers use it comes later. Shareholders also carry royalties to three parties, Israeli rules on moving the technology, and a register where recent rounds were priced at 10 to 16 cents.
SAMSO TAKE On Samso's reading, Identifai is still a clinical-stage company rather than a diagnostics business. The prospectus is detailed about its risks and related parties. Will about 600 patients in real-world care reproduce what 50 high-risk pregnancies showed, and can Identifai get there before larger rivals widen their panels? |
THE OTHER WAY TO READ THIS The small numbers can also be read as normal at this stage. The prospectus notes that BillionToOne launched Unity Confirm, a follow-up test, on a company-sponsored validation of 16 samples. Identifai could also license its analysis to a laboratory, one of the revenue models the prospectus sets out. Identifai says it is in talks with the largest US laboratory networks. On that view, the offer funds two years of work towards a validated product. |
VOCABULARY, IN PLAIN ENGLISH NIPT Non-invasive prenatal testing. A blood test from a pregnant woman that screens fragments of placental DNA in her blood, which usually match the baby's. cfDNA Cell-free DNA. Short pieces of DNA floating in the blood, some of which come from the placenta. Carrier screening A test of a parent to see whether they carry one copy of a faulty gene that could pass to a child. Single-gene condition A disorder caused by a fault in one gene, such as cystic fibrosis. Also called a monogenic disorder. Amniocentesis An invasive test where a needle takes fluid from the womb to test the baby's genes directly. Sensitivity and specificity Sensitivity is how often a test catches a real case. Specificity is how often it correctly clears a healthy one. AUC Area under the curve. A score of how well a test tells affected cases from unaffected ones, where 0.5 is no better than a coin toss and 1.0 is perfect. CLIA The Clinical Laboratory Improvement Amendments, the US federal rules for clinical laboratories. A laboratory-developed test can be offered once the laboratory is certified and the test validated. The company does not expect to need approval from the Food and Drug Administration (FDA). State licences, such as California's, also apply. US billing code A CPT code, the code a US laboratory uses to bill for a test. Having one does not mean an insurer will pay. Going concern An auditor's view on whether a business can keep paying its way for at least the next 12 months. Performance rights Rights that turn into shares only if stated targets are met. Escrow Shares that cannot be sold for a set period after listing. Free float The share of the company that is free to trade. Swap options Options issued by the listed company in exchange for options held in Identifai Israel before the share swap. |
References and sources
Every company figure in this piece comes from the prospectus, quoted as published. Where the prospectus gives two figures for a point this piece discusses, both are shown with the section each came from. Markers such as [R1] point to the numbered entries below. Samso's arithmetic is labelled as Samso's. FIG. 01 is reproduced from the prospectus. FIG. 02 and FIG. 03 are Samso charts built from the prospectus tables. Figures current at 23 September 2026.
[R1] Identifai Genetics Limited (ACN 695 439 993), Prospectus, dated 2 September 2026, lodged with ASIC. Chair's Letter, Key Offer Information, Sections 1, 2.1 to 2.12, 3.3 to 3.5, 4.1 to 4.19, 5, 6, 7, 9.1 to 9.9, 10.7 and 10.13, Annexure B, the IP report by Herzog Patents and CDS, 31 August 2026, and Annexure C, Independent Expert's Report by Pendragon Capital Limited, 31 August 2026. Accessed 23 September 2026 at identifai-genetics.com/prospectus.
[R2] ASX Limited, Upcoming floats and listings. Entry for Identifai Genetics Limited, code ID1, proposed listing 16 October 2026. Accessed 23 September 2026.
Cover photo: Illustrative DNA image from the Identifai Genetics Limited Prospectus, 2 September 2026, Chair's Letter, printed page 5. The prospectus states that undescribed images are for illustration only. Cropped by Samso.
 The Samso Way – Seek the ResearchHere at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story. Our mission is simple. Cut through the noise and spotlight what matters. Genuine stories, grounded insights, and real opportunity. Investors can explore our four core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals. Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn't built in a day, and the Great Wall stood because it took centuries to complete. The Samso Philosophy: Stay curious. Stay sharp. And remember, digging deeper always uncovers the real value. In Life, there is no such thing as a Free Lunch. Never bite off more than you can chew is my parting comment. Happy Investing, and the only four-letter word you need to know is DYOR. To support our independent work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiative for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018. DisclaimerThe information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints. About SamsoSamso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research. Coffee with Samso, Samso Insights, Samso News and Samso Research are four ways into the same work. Interviews, long-form research, short takes on announcements and company-specific studies. Every one of them is about how to think about investing rather than what to buy. Samso News | www.samso.com.au | An Investor Lens on ASX-Listed Companies Samso News is independent research commentary for general information only. Nothing in this article is financial product advice, and it does not take into account any reader's objectives, financial situation or needs. Figures are drawn from public sources believed reliable at the stated dates but are not guaranteed. Market-sensitive numbers change daily. Samso or associated parties may hold positions in, or have commercial arrangements with, companies mentioned. Seek professional advice before making investment decisions. © Samso 2026 · samso.com.au |
Comments